Top Story
Healthcare FinancingRegeneron Pharmaceuticals is venturing into the investment domain, allocating up to $500 million for its new venture capital division, Regeneron Ventures. The initiative, led by former company executives Jay Markowitz and Michael Aberman, aims to support a broad range of health-related companies, extending beyond drug development [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
04/15/2024 05:07 PM ET
Viracta Therapeutics SNGX results announcement
Soligenix has provided investors an update on their recent Phase 1 trial for MarVax. Our analysts provided the following summary:
"Orphan drug designation granted April 15, 2024."
Soligenix rocketed up $0.08 (+21.7%) to $0.47 on [...]
Read More
04/15/2024 05:07 PM ET
Reviva Pharmaceuticals Holdings RVPH earnings announcement
Reviva Pharmaceuticals Holdings revealed their most recent quarterly earnings data, in which EPS ended up lower than estimates. EPS was estimated to be -$0.32, but the actual figure came in at -$0.35.
Investors didn't take [...]
Read More
04/15/2024 05:06 PM ET
Longeveron UBX earnings announcement
Unity Biotechnology revealed their most recent quarterly earnings data, in which EPS ended up higher than estimates. EPS was reported to be -$0.28, which beat the estimated value of -$0.72. Unity Biotechnology's EPS [...]
Read More
04/12/2024 04:43 PM ET
Rallybio Corporation NRSN date announcement
NeuroSense Therapeutics Ltd. plans to announce top-line results for their Phase 2b trial of Prime C - (PARADIGM) on June 30, 2024. Our predictive system gives the drug a 35% chance of making it to [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
